- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.09. | Merck pens $2.1B deal with China's SciBrunch to chase KRAS G12D | ||
| 28.09. | Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drug | ||
| 28.09. | Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal | ||
| 25.09. | Indivior ends PAM drug collab with Addex ahead of Supernus merger | ||
| 25.09. | Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables | ||
| 25.09. | Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil | ||
| 25.09. | ADARx scores upsized $446M IPO, while fellow RNA biotech City Therapeutics maps out Nasdaq plans | ||
| 24.09. | Trump's FDA pick Heidi Overton calls vaccines, mifepristone safe and effective in confirmation hearing | ||
| 24.09. | China's Henlius carves out $440M T-cell engager deal with Amberstone | ||
| 24.09. | Acadia misses mark in Alzheimer's but concludes phase 3 'absolutely worth' pursuing | ||
| 24.09. | Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs | ||
| 24.09. | Merck sees pivotal victory for $3B eye disease prospect | ||
| 24.09. | Lilly puts up $100M, plus billions on the backend, to form 5-target deal with InnoCare | ||
| 23.09. | Enveda reaps $311M series E to feed ambition to become a 'household name' | ||
| 23.09. | Trump's Department of War bets $47M on Flagship biotechs to develop countermeasures | ||
| 23.09. | Boehringer adds $250M to value of Variant pact by expanding into cardiovascular disease | ||
| 23.09. | Immunovant ends cutaneous lupus program after phase 2 flop | ||
| 23.09. | Roche's phase 3 win tees up fight with Novartis for blockbuster kidney disease market | ||
| 22.09. | Novartis secures new radioligand in $900M deal as competition strengthens | ||
| 22.09. | Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition | ||
| 22.09. | Amgen's Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win | ||
| 22.09. | Vertex's midstage data amplify kidney disease market opportunity | ||
| 22.09. | Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets | ||
| 22.09. | Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint | ||
| 22.09. | Roche's GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.